{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:02:00Z","timestamp":1761894120884},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"16","license":[{"start":{"date-parts":[[2005,6,2]],"date-time":"2005-06-02T00:00:00Z","timestamp":1117670400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2005,6,2]],"date-time":"2005-06-02T00:00:00Z","timestamp":1117670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2005,8,1]]},"DOI":"10.1038\/sj.gt.3302561","type":"journal-article","created":{"date-parts":[[2005,6,9]],"date-time":"2005-06-09T10:36:54Z","timestamp":1118313414000},"page":"1253-1263","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Regression of mouse tumours and inhibition of metastases following administration of a Semliki Forest virus vector with enhanced expression of IL-12"],"prefix":"10.1038","volume":"12","author":[{"given":"C P","family":"Chikkanna-Gowda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B J","family":"Sheahan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M N","family":"Fleeton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G J","family":"Atkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,6,2]]},"reference":[{"key":"BF3302561_CR1","first-page":"543","volume":"246","author":"GB Karlsson","year":"2004","unstructured":"Karlsson GB, Liljestrom P . Delivery and expression of heterologous genes in mammalian cells using self-replicating alphavirus vectors. Methods Mol Biol 2004; 246: 543\u2013557.","journal-title":"Methods Mol Biol"},{"key":"BF3302561_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2174\/1566523013349039","volume":"1","author":"K Lundstrom","year":"2001","unstructured":"Lundstrom K . Alphavirus vectors for gene therapy applications. Curr Gene Ther 2001; 1: 19\u201329.","journal-title":"Curr Gene Ther"},{"key":"BF3302561_CR3","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1586\/14760584.2.3.445","volume":"2","author":"K Lundstrom","year":"2003","unstructured":"Lundstrom K . Alphavirus vectors for vaccine production and gene therapy. Expert Rev Vaccines 2003; 2: 447\u2013459.","journal-title":"Expert Rev Vaccines"},{"key":"BF3302561_CR4","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/rmv.360","volume":"12","author":"JO Rayner","year":"2002","unstructured":"Rayner JO, Dryga SA, Kamrud KI . Alphavirus vectors and vaccination. Rev Med Virol 2002; 12: 279\u2013296.","journal-title":"Rev Med Virol"},{"key":"BF3302561_CR5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0014-5793(01)02707-7","volume":"504","author":"K Lundstrom","year":"2001","unstructured":"Lundstrom K et al. Semliki Forest virus vectors: efficient vehicles for in vitro and in vivo gene delivery. FEBS Lett 2001; 504: 99\u2013103.","journal-title":"FEBS Lett"},{"issue":"Part 10","key":"BF3302561_CR6","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1099\/0022-1317-79-10-2405","volume":"79","author":"GM Glasgow","year":"1998","unstructured":"Glasgow GM et al. The Semliki Forest virus vector induces p53-independent apoptosis. J Gen Virol 1998; 79 (Part 10): 2405\u20132410.","journal-title":"J Gen Virol"},{"key":"BF3302561_CR7","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1038\/sj.gt.3301263","volume":"7","author":"AM Murphy","year":"2000","unstructured":"Murphy AM, Morris-Downes MM, Sheahan BJ, Atkins GJ . Inhibition of human lung carcinoma cell growth by apoptosis induction using Semliki Forest virus recombinant particles. Gene Therapy 2000; 7: 1477\u20131482.","journal-title":"Gene Therapy"},{"key":"BF3302561_CR8","first-page":"916","volume":"11","author":"P Berglund","year":"1993","unstructured":"Berglund P et al. Semliki Forest virus expression system: production of conditionally infectious recombinant particles. Biotechnology 1993; 11: 916\u2013920.","journal-title":"Biotechnology"},{"key":"BF3302561_CR9","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1128\/JVI.73.2.1092-1098.1999","volume":"73","author":"C Smerdou","year":"1999","unstructured":"Smerdou C, Liljestr\u00f6m P . Two-helper RNA system for production of recombinant Semliki Forest virus particles. J Virol 1999; 73: 1092\u20131098.","journal-title":"J Virol"},{"key":"BF3302561_CR10","doi-asserted-by":"publisher","first-page":"597","DOI":"10.2174\/1568009043332754","volume":"4","author":"GJ Atkins","year":"2004","unstructured":"Atkins GJ et al. Alphaviruses and their derived vectors as anti-tumor agents. Curr Cancer Drug Targets 2004; 4: 597\u2013607.","journal-title":"Curr Cancer Drug Targets"},{"key":"BF3302561_CR11","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/sj.gt.3300409","volume":"4","author":"J Zhang","year":"1997","unstructured":"Zhang J et al. Cloning of human IL-12 p40 and p35 DNA into the Semliki Forest virus vector: expression of IL-12 in human tumor cells. Gene Therapy 1997; 4: 367\u2013374.","journal-title":"Gene Therapy"},{"key":"BF3302561_CR12","doi-asserted-by":"publisher","first-page":"746","DOI":"10.3171\/jns.2003.99.4.0746","volume":"99","author":"R Yamanaka","year":"2003","unstructured":"Yamanaka R et al. Induction of an antitumor immunological response by an intratumoural injection of dendritic cells pulsed with genetically engineered Semliki Forest virus to produce interleukin-18 combined with the systemic administration of interleukin-12. J Neurosurg 2003; 99: 746\u2013753.","journal-title":"J Neurosurg"},{"key":"BF3302561_CR13","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1002\/ijc.10184","volume":"98","author":"P Colmenero","year":"2002","unstructured":"Colmenero P et al. Immunotherapy with recombinant SFV-replicons expressing the P815A tumor antigen or IL-12 induces tumor regression. Int J Cancer 2002; 98: 554\u2013560.","journal-title":"Int J Cancer"},{"key":"BF3302561_CR14","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1038\/sj.gt.3301004","volume":"6","author":"P Colmenero","year":"1999","unstructured":"Colmenero P, Liljestrom P, Jondal M . Induction of P815 tumor immunity by recombinant Semliki Forest virus expressing the P1A gene. Gene Therapy 1999; 6: 1728\u20131733.","journal-title":"Gene Therapy"},{"key":"BF3302561_CR15","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1016\/S0264-410X(00)00428-X","volume":"19","author":"MM Morris-Downes","year":"2001","unstructured":"Morris-Downes MM et al. Semliki Forest virus-based vaccines: persistence, distribution and pathological analysis in two animal systems. Vaccine 2001; 19: 1978\u20131988.","journal-title":"Vaccine"},{"key":"BF3302561_CR16","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1099\/0022-1317-81-3-749","volume":"81","author":"MN Fleeton","year":"2000","unstructured":"Fleeton MN, Liljestrom P, Sheahan BJ, Atkins GJ . Recombinant Semliki Forest virus particles expressing louping ill virus antigens induce a better protective response than plasmid-based DNA vaccines or an inactivated whole particle vaccine. J Gen Virol 2000; 81: 749\u2013758.","journal-title":"J Gen Virol"},{"key":"BF3302561_CR17","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/j.ymthe.2003.09.010","volume":"8","author":"A Jerusalmi","year":"2003","unstructured":"Jerusalmi A, Morris-Downes MM, Sheahan BJ, Atkins GJ . Effect of intranasal administration of Semliki Forest virus recombinant particles expressing reporter and cytokine genes on the progression of experimental autoimmune encephalomyelitis. Mol Ther 2003; 8: 886\u2013894.","journal-title":"Mol Ther"},{"key":"BF3302561_CR18","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/sj.gt.3300841","volume":"6","author":"C Asselin-Paturel","year":"1999","unstructured":"Asselin-Paturel C et al. Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography. Gene Therapy 1999; 6: 606\u2013615.","journal-title":"Gene Therapy"},{"key":"BF3302561_CR19","first-page":"147","volume":"64","author":"H Ren","year":"2003","unstructured":"Ren H et al. Immunogene therapy of recurrent glioblastoma multiforme with a liposomally encapsulated replication-incompetent Semliki forest virus vector carrying the human interleukin-12 gene\u2013a phase I\/II clinical protocol. J Neurooncol 2003; 64: 147\u2013154.","journal-title":"J Neurooncol"},{"key":"BF3302561_CR20","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1038\/nbt1194-1127","volume":"12","author":"EM Sjoberg","year":"1994","unstructured":"Sjoberg EM, Suomalainen M, Garoff H . A significantly improved Semliki Forest virus expression system based on translation enhancer segments from the viral capsid gene. Biotechnology 1994; 12: 1127\u20131131.","journal-title":"Biotechnology"},{"key":"BF3302561_CR21","first-page":"2531","volume":"56","author":"MP Colombo","year":"1996","unstructured":"Colombo MP et al. Amount of Interleukin 12 available at the tumour site is critical for tumour regression. Cancer Res 1996; 56: 2531\u20132534.","journal-title":"Cancer Res"},{"key":"BF3302561_CR22","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1146\/annurev.iy.13.040195.001343","volume":"13","author":"G Trinchieri","year":"1995","unstructured":"Trinchieri G . Interleukin-12: a proinflmmatory cytokine with immuno-regulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Ann Rev Immunol 1995; 13: 251\u2013276.","journal-title":"Ann Rev Immunol"},{"key":"BF3302561_CR23","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1084\/jem.179.4.1273","volume":"179","author":"R Manetti","year":"1994","unstructured":"Manetti R et al. Interleukin 12 induces stable priming for interferon gamma (IFN-gamma) production during differentiation of human T helper (Th) cells and transient IFN-gamma production in established Th2 cell clones. J Exp Med 1994; 179: 1273\u20131283.","journal-title":"J Exp Med"},{"key":"BF3302561_CR24","doi-asserted-by":"crossref","first-page":"3877","DOI":"10.1182\/blood.V87.9.3877.bloodjournal8793877","volume":"87","author":"C Sgadari","year":"1996","unstructured":"Sgadari C, Angiolillo AL, Tosato G . Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10. Blood 1996; 87: 3877\u20133882.","journal-title":"Blood"},{"key":"BF3302561_CR25","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1016\/S0169-5002(03)00308-8","volume":"42","author":"SS Sridhar","year":"2003","unstructured":"Sridhar SS, Shepherd FA . Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer 2003; 42: S81\u2013S91.","journal-title":"Lung Cancer"},{"key":"BF3302561_CR26","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1099\/0022-1317-13-2-245","volume":"13","author":"SA Aaronson","year":"1971","unstructured":"Aaronson SA, Weaver CA . Characterization of murine sarcoma virus (Kirsten) transformation of mouse and human cells. J Gen Virol 1971; 13: 245\u2013252.","journal-title":"J Gen Virol"},{"key":"BF3302561_CR27","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1084\/jem.135.3.503","volume":"135","author":"JR Stephenson","year":"1972","unstructured":"Stephenson JR, Aaronson SA . Antigenic properties of murine sarcoma virus transformed BALB-3T3 nonproducer cells. J Exp Med 1972; 135: 503\u2013515.","journal-title":"J Exp Med"},{"key":"BF3302561_CR28","first-page":"2142","volume":"40","author":"MG Brattain","year":"1980","unstructured":"Brattain MG et al. Establishment of mouse colonic carcinoma cell lines with different metastatic properties. Cancer Res 1980; 40: 2142\u20132146.","journal-title":"Cancer Res"},{"key":"BF3302561_CR29","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.4049\/jimmunol.154.9.4685","volume":"154","author":"M Wang","year":"1995","unstructured":"Wang M et al. Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol 1995; 154: 4685\u20134692.","journal-title":"J Immunol"},{"key":"BF3302561_CR30","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/sj.gt.3302390","volume":"12","author":"JW Smyth","year":"2005","unstructured":"Smyth JW, Fleeton MN, Sheahan BJ, Atkins GJ . Treatment of rapidly growing K-BALB and CT26 mouse tumours using Semliki Forest virus and its derived vector. Gene Therapy 2005; 12: 147\u2013159.","journal-title":"Gene Therapy"},{"key":"BF3302561_CR31","first-page":"1399","volume":"52","author":"CJ Aslakson","year":"1992","unstructured":"Aslakson CJ, Miller FR . Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 1992; 52: 1399\u20131405.","journal-title":"Cancer Res"},{"key":"BF3302561_CR32","first-page":"1486","volume":"58","author":"BA Pulaski","year":"1998","unstructured":"Pulaski BA, Ostrand-Rosenberg S . Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res 1998; 58: 1486\u20131493.","journal-title":"Cancer Res"},{"key":"BF3302561_CR33","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S1525-0016(03)00236-3","volume":"8","author":"DL Thomas","year":"2003","unstructured":"Thomas DL, Fraser, NW . HSV-1 Therapy of primary tumors reduces the number of metastases in an immune-competent model of metastatic breast cancer. Mol Ther 2003; 8: 543\u2013551.","journal-title":"Mol Ther"},{"key":"BF3302561_CR34","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/j.bbrc.2005.01.061","volume":"328","author":"JQ Gao","year":"2005","unstructured":"Gao JQ et al. A single intratumoral injection of a fiber-mutant adenoviral vector encoding interleukin 12 induces remarkable anti-tumor and anti-metastatic activity in mice with Meth-A fibrosarcoma. Biochem Biophys Res Commun 2005; 328: 1043\u20131050.","journal-title":"Biochem Biophys Res Commun"},{"key":"BF3302561_CR35","doi-asserted-by":"crossref","first-page":"4457","DOI":"10.4049\/jimmunol.160.9.4457","volume":"160","author":"M Toda","year":"1998","unstructured":"Toda M, Martuza RL, Kojima H, Rabkin SD . In situ cancer vaccination: an IL-12 defective vector\/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J Immunol 1998; 160: 4457\u20134464.","journal-title":"J Immunol"},{"key":"BF3302561_CR36","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1084\/jem.178.4.1223","volume":"178","author":"MJ Brunda","year":"1993","unstructured":"Brunda MJ et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993; 178: 1223\u20131230.","journal-title":"J Exp Med"},{"key":"BF3302561_CR37","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1002\/ijc.1495","volume":"94","author":"AM Murphy","year":"2001","unstructured":"Murphy AM, Sheahan BJ, Atkins GJ . Induction of apoptosis in BCL-2-expressing rat prostate cancer cells using the Semliki Forest virus vector. Int J Cancer 2001; 94: 572\u2013578.","journal-title":"Int J Cancer"},{"key":"BF3302561_CR38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1097\/00001813-199502000-00001","volume":"6","author":"JW Rak","year":"1995","unstructured":"Rak JW, St Croix BD, Kerbel RS . Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. Anticancer Drugs 1995; 6: 3\u201318.","journal-title":"Anticancer Drugs"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/3302561.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/3302561","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/3302561.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T09:54:06Z","timestamp":1683107646000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/3302561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6,2]]},"references-count":38,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2005,8,1]]}},"alternative-id":["BF3302561"],"URL":"https:\/\/doi.org\/10.1038\/sj.gt.3302561","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6,2]]},"assertion":[{"value":"12 January 2005","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2005","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2005","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}